Morgan Stanley | sesearcs NORTH AMERICA INSIGHT ~~ Disclosure Section The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C-T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan...
Results for “Novartis Institutes for BioMedical Research”
Search across the indexed text of every released document.
Names that match “Novartis Institutes for BioMedical Research”
1,177 documents found
o account the specific investment o that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any o security or the information in the prospectus or ot! Securities and other financial instruments discussed in this re...
48 Such cases establish a worrying precedent of Chinese intrusion into American academic life. The message from China to US universities is clear: Do not transgress the political no-go zones of the Chinese Communist Party or government, or you will pay a price. Sometimes the pre...
lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change. This report may contain a short-term trading idea or recommendation, which highlights a specific near-term cata lyst or event imp...
Jan Loeys Global Asset Allocation (1-212) 834-5874 The J.P. Morgan View J.P. Morgan [email protected] 09 November 2012 Disclosures Analyst Certification: The research analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts...
Explaining our taste for excessive harm Marc D. Hauser Viking/Penguin For Jacques and Bert Hauser, my parents, my friends, and my reminder that life should be lived to its fullest Hauser Evilicious. Front matter 2 Pleasure is the greatest incentive to evil. ⎯⎯ Plato To witness s...
This research report provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instrument...
MLPF&S or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. MLPF&S or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instru...
this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by t This research report provides general information on other financial instrument or any derivative related to such personal investment advice and it does not take into financial advice regar...
Research Analysts US Banks Erika Najarian Research Analyst MLPF&S +1 646 855 1584 [email protected] Ebrahim H. Poonawala Research Analyst MLPF&S +1 646 743 0490 [email protected] Michael Liu Research Analyst MLPF&S +1 646 855 3874 [email protected] Brandon B...
Disclosures Important Disclosures FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS r...
Inference: International Review of Science Feedback & Comments November 2018 David Adger Professor of Linguistics at Queen Mary University of London. “Thanks for the hardcopy of the last issue. It was really interesting,” Egil Asprem Associate Professor in the History of Religio...
From: Gino Yu Sent: 12/17/2016 12:35:06 PM To: jeffrey E. [[email protected]] Subject: Re: Schulte Research: Deep dives into PRC fin tech ownership and Trump cabinet ownership. (DO NOT FORWARD) Attachments: mime-attachment.png; mime-attachment.gif; mime-attachment.jpg Importa...
Sprout Capital VIL, L.P. (Healthcare Technology Portfolio) $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,],K,L,M and N in this Appendix. Gross Multiple Gross Vintage Total Realized Unrealize Total (Realized Multiple Company Year Cost Value d Value Valu...
…ing and outreach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased cli...